The pathogenesis of endometrial carcinomas at menopause: facts and figures

Efthimios Sivridis, Alexandra Giatromanolaki

Department of Pathology,
Democritus University of Thrace
Medical School, and University
General Hospital of
Alexandroupolis,
Alexandroupolis, Greece

Correspondence to

Efthimios Sivridis, Department
of Pathology, Democritus
University of Thrace Medical
School, and University General
Hospital of Alexandroupolis, PO
Box 128, Alexandroupolis
68100, Greece;
esivrid@med.duth.gr

Accepted 18 January 2011

Published Online First
17 February 2011

ABSTRACT

Almost a third of the life of a woman is now postmenopausal, and during this period over 80% of endometrial carcinomas develop. This is by far the most common gynaecological malignancy in the industrialised world and, probably, the less completely understood with regard to its pathogenesis after the menopause. For while it is generally thought that these neoplasms are non-oestrogen-induced, we are, at the same time, informed that oestrogenic stimulation is continuous during menopause through increases to oestrone formation in the adipose tissue from androgens of adrenal and ovarian origin. Furthermore, the postmenopausal endometrium has been typified as atrophic, which is indeed true, but is also implied as being inactive, which in fact it is not; in most cases, the postmenopausal endometrium appears to be weakly proliferative with potential to give rise to an endometrial carcinoma. It is also assumed that postmenopausal endometrial tumours are predominantly of serous papillary and clear cell type, and, in general, they are not well-differentiated endometrioid carcinomas; in reality, no more than 15% are serous papillary and clear cell carcinomas, and no less than 55% are well-differentiated endometrioid neoplasms. The overall prognosis is presumed to be poor, yet postmenopausal patients harbouring well-differentiated endometrioid carcinomas have the same excellent prognosis as those premenopausal women having endometrioid tumours of similar grade and stage. This brief account of endometrial carcinogenesis at menopause re-evaluates these issues and, in the light of new and old evidence, proposes the separation of G1 endometrioid adenocarcinomas (low-grade tumours) from all others (high-grade tumours).

INTRODUCTION

The study of endometrial carcinoma at menopause presents an interesting challenge. The tumour is, on the whole, the commonest gynaecological malignancy in the industrialised world,^{1–3} comprising 4% of all cancers in women, and a lifetime risk of 2–3%.⁴ It is a disease of ageing, with over 80% of cases occurring during the menopause.^{5–7}

This is a paradox, for endometrial carcinomas are hormone-dependent tumours and, as such, have been associated with high circulating levels of unopposed oestrogens (oestrogens in the absence of progesterone). Yet, at the time these tumours most commonly occur, that is during menopause, oestrogen secretion is waning. To acknowledge that prolonged oestrogenic stimulation of the endometrium occurs in carcinomas developing in the young (type I carcinomas), while postmenopausal women

simply lack such a stimulus (type II carcinomas),^{8–11} would have us understand not what the mechanism of the disease is in older women, but what it is not.

As a consequence of ovarian failure, endometrial carcinomas during menopause have been presumed to originate from a background of endometrial atrophy and inactivity.^{8–11} There is little doubt that the postmenopausal endometria are atrophic, but this does not necessarily mean that they are also inactive—a contention that needs further thought. How could a state of ‘inertia’ give rise to a new growth, even if this is an abortive growth?

It is true that serous papillary and clear cell carcinomas, which are hosted almost exclusively by the postmenopausal uteri, are lethal tumours.^{12–14} The question remains, of course, how prevalent these tumours are to affect an overall prognosis? And what is the frequency of other postmenopausal endometrial tumours that are known to have a much better outcome? These are issues that are becoming increasingly important.

This review will focus on endometrial carcinomas developing during menopause, not simply because they are more common, but because their pathogenesis is less completely understood; the pathogenesis of tumours arising in young women during their reproductive years has been precisely delineated and requires no further consideration.^{12–15}

PATHOGENETIC MECHANISM IN ENDOMETRIAL CARCINOMAS AT MENOPAUSE: YET AGAIN, AN OESTROGENIC MILIEU

The belief that postmenopausal endometrial carcinogenesis is not oestrogen induced rests largely upon the paucity of ovarian function that follows the menopause and the presence of a thin atrophic endometrium. This may all be true, but should not be allowed to detract from the fact that oestrogen production continues after the menopause.^{16 17} For indeed, in addition to oestrogens being secreted by the developing ovarian follicle during reproductive life, they are also secreted during the menopause from androgens produced by the adrenal glands and the non-specialised ovarian stroma.^{16 18 19} The secretion, mainly in the form of androstenedione and testosterone, is increased notably during this period,^{20–22} in parallel with an increased conversion of androgens to oestrone.^{23 24}

The reaction takes place in peripheral tissues, mainly in adipose tissue, through the cytochrome P450 aromatase, and has been estimated to be 3–5 times above normal levels of secretion^{23 24}; it is further enhanced with increasing body weight and advanced age.^{18 25–29} The extrafollicular oestrogens produced can freely diffuse to the endometrium as

biologically active hormones, as they are unbound to sex-hormone-binding globulin.^{20 30} This is because the level of sex-hormone-binding globulin is decreased in obese postmenopausal women.^{16 30–36} It is worth mentioning that although all postmenopausal women are capable of converting androgens to oestrogens under 'physiological' conditions,³⁷ only those that have a high efficiency in doing so are at risk of developing endometrial cancer^{38 39}; indeed, extrafollicular oestrogen concentrations are significantly higher in women with endometrial carcinomas relative to healthy controls.^{22 26 34} It is possible that some of the conversion occurs in the endometrium, through endometrial aromatase cytochrome P450, thus increasing oestrogen concentrations at the endometrial level.^{21 40}

The mechanism of conversion of androgen to oestrogen assumes a dominant role under the pathological conditions of oestrogen-secreting ovarian neoplasms, mainly granulosa and thecal cell tumours, and in a background of cortical stromal hyperplasia and hyperthecosis.^{21 41} Nulliparity or low parity, which is associated with failure of ovulation, and persistence of the mature follicle and prolonged high oestrogen levels without corpus luteum formation, may enhance the possibility of developing endometrial carcinoma by increasing the exposure time of the endometrium to endogenous oestrogens.⁴²

It is, however, only the therapeutic intervention in the uterus, specifically in the form of hormone replacement therapy, which illustrates clearly the role of oestrogens in postmenopausal endometrial carcinogenesis.^{35 38 43–47} This practice, which simulates precisely the naturally occurring 'prolonged oestrogenic stimulation of the endometrium, unopposed by progesterone action', has been associated with an 8-fold to 15-fold increase in incidence of endometrial carcinoma.^{48–53} Most interestingly, the risk was reduced considerably with the addition of progestins.^{45 54–56}

It is thus apparent that an oestrogenic milieu does exist in the postmenopausal endometrium and may account, to a certain extent, for the observed increases of endometrial cancer in older women.^{34 38 57} Obesity, as the driving force of the conversion mechanism, has been implicated in about 40% of all endometrial cancer cases in postmenopausal women.^{58–62} Notably, oestrone and oestradiol concentrations have been shown to be significantly higher in women with endometrial cancer compared with healthy women, and also in endometrial carcinoma cell lines compared with unaffected controls.⁶³ Oestrone, while a weak oestrogen, has proved to be more effective than oestradiol and oestriol in promoting endometrial carcinomas in mice.⁶⁴

THE DYNAMICS OF AN ATROPHIC, BUT PROLIFERATING/NON-INACTIVE POSTMENOPAUSAL ENDOMETRIUM

Oestrogen drive stimulation appears to be a common pathogenic mechanism in postmenopausal endometrial carcinomas, particularly when it acts continuously and in relatively increased concentrations on its target tissue: the endometrium.^{5 35 38 59 65} But what are the changes that a 'physiological' uterine mucosa assumes following the decline of ovarian function?

At first, the non-cycling, yet normal, asymptomatic postmenopausal endometrium becomes gradually atrophic, assuming a shallow uterine mucosa, 2.2 mm thick, with loss of distinction between the basal layer and the functional layer.⁶⁵ The endometrial glands may initially retain some proliferative activity, albeit weak,^{65–67} but, with further decline of oestrogen secretion, the uterine mucosa becomes functionally inactive.⁶⁵ It is composed of small tubular glands, widely spaced, and these are lined by cuboidal indeterminate epithelium, showing neither

secretory nor proliferative activity; the stroma is dense and fibrous. Finally, with complete absence of ovarian function,⁶⁸ the endometrium falls into cystic atrophy,⁶⁹ having a thin uterine mucosa, cystically dilated endometrial glands, and a flattened inactive epithelium.

The loss of the negative feedback of oestrogens on the hypothalamus, combined with the loss of the restraining action of inhibin B on the secretion of follicle-stimulating hormone, provoke a marked increase in serum gonadotropins, predominantly pituitary follicle stimulating hormone.^{70–72} This, in turn, stimulates the production of androgens, mainly androstenedione and testosterone, by the non-specialised ovarian stroma. Peripheral conversion of ovarian and adrenal androgens to oestrone through aromatisation in the adipose tissues becomes the primary source of endogenous oestrogens in postmenopausal women and may be sufficient to stimulate the endometrium.⁵⁹ Subject to these conditions, the endometrium, while remaining atrophic, abandons its state of inertia and resumes its weak proliferative activity,^{66 67 73} exemplified by focal proliferation of endometrial glands, with moderate tortuosity, pseudostratification and infrequent mitoses.

In reality, most asymptomatic non-cycling endometria are thin and atrophic,^{65–67} but only half of the cases are inactive.⁶⁵ The remaining show a weak proliferative activity,^{65–67} indicative of an endometrium that receives, and apparently responds to, continuous low level oestrogenic messages. This was inferred from the presence of morphologically active endometrial glands, having a full complement of oestrogen receptor, progesterone receptor and epidermal growth factor receptor, and an increased proliferative activity (MIB-1), set in a highly vascular endometrial stroma.^{65 74 75}

The implications of these findings are obvious. Under the influence of relatively high levels of unopposed oestrogenic stimulation, the postmenopausal endometrium may develop mild architectural changes and turn into the so-called disordered proliferative endometrium,^{69 73} or it may display increasing degrees of architectural and cytological atypias, and take the form of atypical endometrial hyperplasia (endometrial intraepithelial neoplasia)^{66 67 76 77} or endometrial intraepithelial carcinoma,^{78 79} from which an endometrial carcinoma can develop.

These observations may explain the latent potential that an atrophic, but proliferating (non-inactive), endometrium may have to assume various forms of postmenopausal proliferative activity and through them, if not directly, give rise to an endometrial adenocarcinoma.⁶⁵

THE PREVALENCE OF THE VARIOUS TUMOUR CELL TYPES: A CLASSIFICATION SCHEME WITH PROGNOSTIC VALUE

It is true that endometrial carcinomas occurring during the reproductive years are all, or nearly all, well-differentiated endometrioid adenocarcinomas (so-called type I carcinomas). However, the reverse contention may not be necessarily correct as, indeed, only a quarter of the tumours developing after the menopause are non-endometrioid carcinomas. In addition, it is not always realised that as many as 55% of endometrial carcinomas at menopause are also of the G1 endometrioid type, (figure 1A) and a further 20% are G2/G3 endometrioid tumours (figure 1B).^{5 15 73 80 81} The prototypes of non-endometrioid carcinomas (type II carcinomas), the serous papillary (figure 1C) and the clear cell (figure 1D) tumours, share no more than 15% of the total,^{13 14 82–88} and there is, of course, a group of around 10% of rather unusual types of non-endometrioid carcinomas.⁸¹ (box 1).

Figure 1 Basic histological forms of endometrial carcinoma at menopause. (A) Grade 1 endometrioid adenocarcinoma, (B) grade 3 endometrioid carcinoma, (C) serous papillary carcinoma, (D) clear cell carcinoma.

Obviously, these data have an impact on patient survival. The many well-differentiated endometrioid adenocarcinomas originating from an atrophic postmenopausal endometrium are similar in all respects to those endometrioid adenocarcinomas of equal grade and stage that are associated with atypical hyperplasia in young premenopausal women^{5 73}; they all have an almost excellent prognosis, with reported 5-year survival rates varying from 87% to 97%.^{89 90} The serous papillary and clear cell carcinomas, on the other hand, are aggressive tumours that have an increased metastatic potential, high tendency for relapses, and a 5-year survival rate that may be as low as 15%,^{12 91} although the usual survival rate quoted has varied from 30% to 68%.^{12 85 92–100} With the exception of mucinous carcinomas (see below), the moderately and poorly differentiated endometrioid carcinomas and the various non-endometrioid types have a similar ominous clinical course (box 1).^{101–103} Recently, Soslow *et al* who investigated a series of high-grade endometrial neoplasms of different histological type, namely G3 endometrioid, serous papillary and clear cell carcinomas, found that they were all associated with an almost similar clinical outcome; the corresponding 5-year survival rates of 45%, 36% and 50% were not statistically significant.¹⁰³

There can be no doubt that a diverse collection of lethal tumours, such as the serous papillary, the clear cell, other non-endometrioid tumours, together with the G2/G3 endometrioid carcinomas, would make the survival of postmenopausal women worse. Yet, it has to be admitted that these tumours attracted a degree of attention disproportionate to their frequency, while the many well-differentiated endometrioid adenocarcinomas of the postmenopausal age, with an unquestionably favourable prognosis, have been almost totally ignored. Thus, the longstanding assertion that endometrial carcinomas developing during menopause are of poor prognosis is too wide a generalisation.

It has been thus far illustrated that endometrial carcinomas occurring at menopause form a heterogeneous group of tumours,

the prognosis of which depends on the histological type (whether endometrioid or non endometrioid) (box 1) and on the degree of differentiation (whether G1, G2 or G3) (box 2).^{104–107} However, grading of endometrioid adenocarcinomas can be highly subjective, particularly in distinguishing between

Box 1 Classification of endometrial carcinomas at menopause

Low-grade endometrial adenocarcinomas

- ▶ Endometrioid
 - Usual type
 - With squamous differentiation
 - Papillary
 - Secretory
 - Ciliated cell
 - Sertoliform
 - With trophoblastic differentiation
 - Oxyphil cell
- ▶ Non-endometrioid
 - Mucinous

High-grade endometrial carcinomas

- ▶ Endometrioid
 - Solid type
- ▶ Non-endometrioid
 - Serous papillary
 - Clear cell
 - Squamous cell
 - Transitional cell
 - Mixed types
 - Undifferentiated
 - Verrucous
 - 'Glassy cell'

Box 2 The three-level FIGO grading system for endometrial adenocarcinomas of the endometrioid cell type compared with proposed binary tumour grading systems

1988 FIGO grading^{*145}

- ▶ G1: composed almost exclusively of well-formed glands; ≤5% solid (non-squamous) component
- ▶ G2: 6–50% solid (non-squamous) component
- ▶ G3: >50% solid (non-squamous) component; lacks well formed glands

Taylor *et al* (1999)¹¹²

- ▶ Low grade: ≤20% solid (non squamous) growth
- ▶ High grade: >20% solid (non squamous) growth

Lax *et al* (2000)^{†111}

- ▶ Low grade: ≤50% solid growth‡, expansive/pushing tumour border, no evidence of tumour cell necrosis
- ▶ High grade: >50% solid growth‡, infiltrative growth pattern, tumour cell necrosis

Scholten *et al* (2004)¹¹⁰

- ▶ Low grade: ≤50% solid growth‡
- ▶ High grade: >50% solid growth‡

Alkushi *et al* (2005)^{†109}

- ▶ Low grade: predominance of glandular pattern, mild to moderate atypia, ≤6 mitoses per HPF
- ▶ High grade: Predominance of papillary or solid growth, severe nuclear atypia, >6 mitoses per HPF

FIGO, International Federation of Gynecology and Obstetrics; HPF, high-power field.

*Notes on FIGO grading: notable nuclear atypia, inappropriate for the architectural grade (particularly pleomorphism and prominent nucleoli), raises the grade from 1 to 2 or from 2 to 3¹⁴⁶, by convention, serous papillary and clear cell carcinomas are considered grade 3; adenocarcinomas with squamous differentiation are graded according to the nuclear grade of the glandular component.

†High grade if at least two of the three criteria are present.

‡Irrespective of squamous or non-squamous differentiation.

International Federation of Gynecology and Obstetrics (FIGO) grade G1 (<5% solid growth) and FIGO G2 (>5% solid growth) tumours^{73 105} and, indeed, many G2 endometrioid adenocarcinomas may appear less aggressive than G1 endometrioid adenocarcinomas. Nevertheless, it has been suggested that

a binary grading system that divides endometrial tumours into low-grade and high-grade is more effective in assessing prognosis and has greater reproducibility than the presently used three-tier FIGO grading system. This has been claimed for all two-tier grading systems proposed,^{108–112} whether based solely on the proportion of solid growth,^{110 112} or on solid growth and additional histological criteria, such as mode of invasion and tumour cell necrosis¹¹¹ or nuclear atypia and mitotic activity¹⁰⁹ (box 2) (for a full discussion, see the recent review by Clarke and Gilks¹⁰⁵).

In this context, the endometrial carcinomas may be conveniently divided, in terms of prognosis, into groups of low-grade and high-grade. The first, and apparently larger, group of tumours is represented by the well-differentiated endometrioid carcinomas and the mucinous tumours; the mucin-secreting adenocarcinomas have a remarkable resemblance to G1 endometrioid neoplasms, and occur with a frequency of 0.6% to 5%⁸⁷ and a 5-year survival rate of 95%.^{10 81 113–116} The second group of endometrial carcinomas comprises the high-grade serous papillary and the clear cell carcinomas, the G2 and G3 endometrioid neoplasms, and the various unusual types of non-endometrioid carcinomas. This system is meant to be prognostically meaningful and may lead to individualisation of treatment. Box 1 outlines the taxonomic scheme proffered, and table 1 summarises the specific features of the various tumours.

GENETIC SUBGROUPS OF ENDOMETRIAL CARCINOMA: WHAT IS THE MESSAGE?

Our option to separate G1 endometrioid adenocarcinomas from those of G2/3 and the non-endometrioid tumours appears to be also justified in terms of molecular genetic changes. In the first instance, it was shown that endometrioid and serous papillary carcinomas express genetic aberrations with different frequencies (table 2). The endometrioid adenocarcinomas display, as a whole, a high incidence of mutations in the PTEN^{117–120} and K-ras genes,^{121–123} and often contain microsatellite instability^{122 124–127} and a near diploid karyotype.^{128–130} In contrast, the serous papillary carcinomas rarely, if ever, exhibit PTEN and K-ras mutations, microsatellite instability or a diploid karyotype, but are more likely to have p53 mutations^{122 131–135} and a non-diploid (aneuploid) karyotype.^{128–130}

There has been some evidence, however, that in addition to such genetic differences existing between various types of endometrial carcinoma (ie, serous papillary versus

Table 1 Specific features of low-grade and high-grade endometrial carcinomas developing during menopause

Feature	Low-grade endometrial carcinoma	High-grade endometrial carcinoma
Age	Perimenopausal and postmenopausal years	Perimenopausal and postmenopausal years
Tumour-free endometrium adjacent to carcinoma	Atrophic (but not inactive); usually weakly proliferative	Atrophic (but not inactive); usually weakly proliferative
Pathogenesis	Extra-ovarian oestrone stimulation	Extra-ovarian oestrone stimulation
Frequency	Common (about 55%)	Less common (about 45%)
Precursor lesion	Rarely, but if present: atypical endometrial hyperplasia	Presumed to be less uncommon: endometrial intraepithelial carcinoma/endometrial glandular dysplasia ('p53 signatures')
Histological type	Endometrioid carcinoma G1 (55%), mucinous carcinoma G1	Serous papillary carcinoma (10%), clear cell carcinoma (5%), endometrioid carcinoma G2/G3 (20%), non-endometrioid carcinoma (10%)
Differentiation	G1	G2–G3
Receptor state	ER rich, PR rich	ER rich or ER poor, PR rich or PR poor
Myometrial invasion	Nil to inner 1/3	Inner 1/3 to 3/3
Lymphatic invasion	Less common	Common
Stage	I	I–IV
Prognosis	Almost excellent	Poor

ER, oestrogen receptor; PR, progesterone receptor.

Table 2 The main gene expression profiles in endometrioid and serous papillary carcinomas of the endometrium

	Endometrioid carcinoma (%)	Serous papillary carcinoma (%)	References
PTEN mutations	37–83	0–5	117–120
K-ras mutations	10–26	0–2	121–123
Microsatellite instability	15–28	0	122 124–127
β-Catenin	14–44	0–5	144 147–149
p53	14–20	53–96	122 131–135
Aneuploidy	10–18	85–95	128–130
E-cadherin	10–20	80–90	139–141

endometrioid), they also exist between the various grades of endometrioid neoplasms. For example, the high-grade endometrioid carcinomas tend to follow the molecular patterns expressed by the serous papillary carcinomas rather than those of low-grade endometrioid neoplasms. More specifically, p53 mutations have been reported to occur in 93% of serous papillary carcinomas, but in only 17% of endometrioid carcinomas. Yet, endometrioid carcinomas, assessed by tumour grade, have been found to express p53 mutations only if they are high-grade: G3, 43%; G2, 8%; G1, 0%.^{122 134 136} In another study, p53 mutations were recorded in 82% of serous papillary carcinomas, 57% in G3 endometrioid disease, and 14% in the combined group of G1/G2 endometrioid carcinomas.¹³⁴

It is worth noting that p53 defects were less frequent in clear cell carcinomas than in serous papillary tumours,¹¹⁴ and any difference in p53 expression between clear cell and G3 endometrioid carcinomas was not statistically significant.¹¹⁴ This tendency was repeated by immunohistochemistry. Over-expression of p53 was more frequent in non-endometrioid than in endometrioid carcinomas (38% versus 13%, respectively); however, when endometrioid carcinomas were assessed as a function of tumour differentiation, the G3 endometrioid carcinomas almost reached the frequency of the non-endometrioid tumours (36% versus 38%); the reported values for G2 and G1 endometrioid carcinomas were 20% and 8%, respectively.¹³⁷

Likewise, the genetic aberrations have been found to be more frequent and more complex in serous papillary than in endometrioid carcinomas, with means of 5.7 versus 1.5 aberrations per tumour, respectively.¹³⁸ However, when endometrioid carcinomas were assessed as a function of tumour grade, the mean numbers of changes per sample were 2.3 for G3, 2.2 for G2, and 0.73 for G1 carcinomas.

E-cadherin, which is generally considered as a suppressor of tumour progression,^{139–141} has been found to be associated with reduced expression in serous papillary, clear cell and the G3 endometrioid carcinomas, when the latter were evaluated by tumour grade.^{124–144}

Similar trends have been manifested in ploidy-related parameters. Thus, the proportion of non-diploid karyotypes in various studies ranged from 70–95% in serous papillary carcinomas, and from 24–70% in G3 endometrioid carcinomas^{128–130}; in fact, the highest values of G3 endometrioid tumours have been identified with the lowest values of serous papillary carcinomas. The corresponding figures for G2 and G1 endometrioid carcinomas were 11–14% and 9–11%, respectively.^{128 130}

Others have found that G3 endometrioid carcinomas may even exceed the serous papillary carcinomas in frequency of ploidy-related parameters; tetraploidy, for example, has been reported as being expressed in 21% of G3 endometrioid carcinomas versus 18% of serious papillary tumours.¹³⁰ The corresponding tetraploid values for G2 and G1 endometrioid

carcinomas were 5% and 3%, respectively.¹³⁰ It appears, therefore, that the proposed taxonomy for endometrial carcinomas has considerable merit in this respect.

CONCLUDING REMARKS

Despite the decline in ovarian function that follows menopause, oestrogen, but not progesterone, synthesis continuous during the postmenopausal years through increases to oestrone formation from androgens of adrenal and ovarian origin. The reaction, which occurs in the adipose tissue and enhances with increasing body weight and advanced age, may occasionally produce relatively high oestrogen concentrations.

Under such conditions, the endometrium, while remaining thin and atrophic, assumes a weak proliferative activity, which is capable of giving genesis to various forms of proliferation and potentially to endometrial carcinoma. Indeed, there is a dramatic increase in the incidence of endometrial carcinoma during the postmenopausal years; this may suggest that oestrone, a weak oestrogen, may play the same pathogenetic role in the development of endometrial carcinoma as does a potent oestrogen, oestradiol, in young premenopausal women. If this is true, as it appears, endometrial carcinomas should no longer be regarded as 'oestrogen dependent' (type I carcinomas occurring in premenopausal women) or 'oestrogen independent' (type II carcinomas developing at menopause), but rather as neoplasms of having varying degrees of hormone dependence.

Take-home messages

- ▶ Endometrial carcinoma is predominantly a disease of menopause, but it also arises in a setting of oestrogenic milieu. This should not be considered a paradox, since oestrogens are produced not only by the developing ovarian follicle during the reproductive years, but also at menopause from the peripheral conversion (aromatization) of androgens produced by the adrenal glands and the non-specialised ovarian stroma. Obesity and advanced age are contributory factors. Oestrogen replacement therapy also plays a major role.
- ▶ Postmenopausal oestrogenic stimulation, when somewhat increased, it is associated with an endometrium which, while atrophic, displays a weak proliferative activity; this is the background upon which endometrial carcinoma most commonly arises.
- ▶ Serous papillary and clear cell carcinomas (so-called type II carcinomas) are lethal grade 3 tumours, developing almost exclusively during menopause, but these form only 15% of the total number of tumours. In contrast, the low-grade endometrioid adenocarcinomas, which form nearly 55% of tumours developing in postmenopausal women, have the same favourable prognosis as do the endometrioid adenocarcinomas of similar grade arising in young premenopausal women (so-called type I carcinomas).
- ▶ Thus, endometrial carcinoma, as a postmenopausal disease, is not invariably of poor prognosis, as it is generally assumed, and it will be convenient, and indeed necessary, to separate the low-grade/favourable prognosis endometrioid adenocarcinomas from the high-grade/unfavourable prognosis G2 and 3 endometrioid carcinomas and those of the non-endometrioid type.

Interactive multiple choice questions

This JCP review article has an accompanying set of multiple choice questions (MCQs). To access the questions, click on BMJ Learning: Take this module on BMJ Learning from the content box at the top right and bottom left of the online article. For more information please go to: <http://jcp.bmj.com/education> Please note: the MCQs are hosted on BMJ Learning—the best available learning website for medical professionals from the BMJ Group. If prompted, subscribers must sign into JCP with their journal's username and password. All users must also complete a one-time registration on BMJ Learning and subsequently log in (with a BMJ Learning username and password) on every visit.

In contrast to what it is generally believed, many endometrial carcinomas occurring during the menopause are well-differentiated endometrioid adenocarcinomas having an almost excellent prognosis. The remaining cases are lethal tumours, more or less. Apart from morphology and prognosis, the two groups appear to be different in terms of molecular genetic frequencies. Their taxonomic separation would allow individualisation of treatment.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **AIHW.** Australian Institute of Health and Welfare and the Australian Association of Cancer Registries. *Cancer in Australia 1999*. Canberra: AIHW and Australian Association of Cancer Registries, 2002.
2. **Bray F, Dos Santos Silva I, Moller H, et al.** Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. *Cancer Epidemiol Biomarkers Prev* 2005;**14**:1132–42.
3. **Jemal A, Siegel R, Ward E, et al.** Cancer statistics, 2009. *CA Cancer J Clin* 2009;**59**:225–49.
4. **Engelsen IB, Akslen LA, Salvesen HB.** Biologic markers in endometrial cancer treatment. *APMIS* 2009;**117**:693–707.
5. **Sivridis E, Fox H, Buckley C.** Endometrial carcinoma: two or three entities? *Int J Gynecol Cancer* 1998;**8**:183–8.
6. **Trimble CL, Kauderer J, Zaino R, et al.** Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a gynecologic oncology group study. *Cancer* 2006;**106**:812–19.
7. **Uharcek P.** Prognostic factors in endometrial carcinoma. *J Obstet Gynaecol Res* 2008;**34**:776–83.
8. **Bokhman JV.** Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* 1983;**15**:10–17.
9. **Deligdisch L, Cohen CJ.** Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. *Cancer* 1985;**56**:1452–5.
10. **Deligdisch L, Holinka CF.** Progesterone receptors in two groups of endometrial carcinoma. *Cancer* 1986;**57**:1385–8.
11. **Sherman ME.** Theories of endometrial carcinogenesis: a multidisciplinary approach. *Mod Pathol* 2000;**13**:295–308.
12. **Christopherson WM, Alberhasky RC, Connelly PJ.** Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. *Cancer* 1982;**49**:1511–23.
13. **Ciriano FD Jr, Robboy SJ, Dodge RK, et al.** Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. *Gynecol Oncol* 1999;**74**:385–94.
14. **Trope C, Kristensen GB, Abeler VM.** Clear-cell and papillary serous cancer: treatment options. *Best Pract Res Clin Obstet Gynaecol* 2001;**15**:433–46.
15. **Sivridis E.** *An Immunohistochemical Study of Endometrial Hyperplasia and Neoplasia*. PhD thesis. UK: University of Manchester, 1986.
16. **Siitari PK.** Steroid hormones and endometrial cancer. *Cancer Res* 1978;**38**:4360–6.
17. **Judd HL.** Hormonal dynamics associated with the menopause. *Clin Obstet Gynecol* 1986;**19**:775–88.
18. **Cleland WH, Mendelson CR, Simpson ER.** Effects of aging and obesity on aromatase activity of human adipose cells. *J Clin Endocrinol Metab* 1985;**60**:174–7.
19. **Sasano H, Harada N.** Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. *Endocr Rev* 1998;**19**:593–607.
20. **Siitari PK.** Adipose tissue as a source of hormones. *Am J Clin Nutr* 1987;**45** (1 Suppl):277–82.
21. **Nagamani M, Hannigan EV, Dillard EA Jr, et al.** Ovarian steroid secretion in postmenopausal women with and without endometrial cancer. *J Clin Endocrinol Metab* 1986;**62**:508–12.
22. **Mollerstrom G, Carlstrom K, Lagrelid A, et al.** Is there an altered steroid profile in patients with endometrial carcinoma? *Cancer* 1993;**72**:173–81.
23. **Knab DR.** Estrogen and endometrial carcinoma. *Obstet Gynecol Surv* 1977;**32**:267–81.
24. **Tseng L, Mazella J, Funt MI, et al.** Preliminary studies of aromatase in human neoplastic endometrium. *Obstet Gynecol* 1984;**63**:150–4.
25. **Wynder EL, Escher GC, Mantel N.** An epidemiological investigation of cancer of the endometrium. *Cancer* 1966;**19**:489–520.
26. **Hemzell DL, Grodin JM, Brenner PF, et al.** Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. *J Clin Endocrinol Metab* 1974;**38**:476–9.
27. **Southcott BM.** Carcinoma of the endometrium. *Drugs* 2001;**61**:1395–405.
28. **Lachance JA, Everett EN, Greer B, et al.** The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. *Gynecol Oncol* 2006;**101**:470–5.
29. **Burbos N, Musonda P, Giarenis I, et al.** Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. *Br J Cancer* 2010;**102**:1201–6.
30. **Allen NE, Key TJ, Dossus L, et al.** Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer* 2008;**15**:485–97.
31. **Kirschner MA, Schneider G, Ertel NH, et al.** Obesity, androgens, estrogens, and cancer risk. *Cancer Res* 1982;**42**(8 Suppl):3281–5.
32. **Pettersson B, Bergstrom R, Johansson ED.** Serum estrogens and androgens in women with endometrial carcinoma. *Gynecol Oncol* 1986;**25**:223–33.
33. **Azziz R.** Reproductive endocrinologic alterations in female asymptomatic obesity. *Fertil Steril* 1989;**52**:703–25.
34. **Nyholm HC, Nielsen AL, Lyndrup J, et al.** Plasma oestrogens in postmenopausal women with endometrial cancer. *Br J Obstet Gynaecol* 1993;**100**:1115–19.
35. **Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al.** Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. *Br J Cancer* 2001;**84**:975–81.
36. **Lukanova A, Lundin E, Micheli A, et al.** Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. *Int J Cancer* 2004;**108**:425–32.
37. **Chang RJ, Judd HL.** The ovary after menopause. *Clin Obstet Gynecol* 1981;**24**:181–91.
38. **Potischman N, Hoover RN, Brinton LA, et al.** Case-control study of endogenous steroid hormones and endometrial cancer. *J Natl Cancer Inst* 1996;**88**:1127–35.
39. **Aiman J.** Age, estrogen, and the endometrium. *Clin Obstet Gynecol* 1981;**24**:193–202.
40. **Tseng L, Mazella J, Mann WJ, et al.** Estrogen synthesis in normal and malignant human endometrium. *J Clin Endocrinol Metab* 1982;**55**:1029–31.
41. **Jongen VH, Hollema H, Van Der Zee AG, et al.** Aromatase in the context of breast and endometrial cancer. A review. *Minerva Endocrinol* 2006;**31**:47–60.
42. **Fox H, Sen DK.** A controlled study of the constitutional stigmata of endometrial adenocarcinoma. *Br J Cancer* 1970;**24**:30–6.
43. **Murphy LJ, Ghahary A.** Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. *Endocr Rev* 1990;**11**:443–53.
44. **Rose PG.** Endometrial carcinoma. *N Engl J Med* 1996;**335**:640–9.
45. **Weiss NS, Hill DA.** Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. *Maturitas* 1996;**23**:235–9.
46. **Emons G, Fleckenstein G, Hinney B, et al.** Hormonal interactions in endometrial cancer. *Endocr Relat Cancer* 2000;**7**:227–42.
47. **Lundberg V, Tolonen H, Stegmayr B, et al.** Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. *Maturitas* 2004;**48**:39–49.
48. **Ziel HK, Finkle WD.** Increased risk of endometrial carcinoma among users of conjugated estrogens. *N Engl J Med* 1975;**293**:1167–70.
49. **Mack TM, Pike MC, Henderson BE, et al.** Estrogens and endometrial cancer in a retirement community. *N Engl J Med* 1976;**294**:1262–7.
50. **MacDonald PC, Edman CD, Hemzell DL, et al.** Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. *Am J Obstet Gynecol* 1978;**130**:448–55.
51. **Antunes CM, Stolley PD, Rosenshein NB, et al.** Endometrial cancer and estrogen use. Report of a large case-control study. *N Engl J Med* 1979;**300**:9–13.
52. **Grady D, Gebretsadik T, Kerlikowske K, et al.** Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol* 1995;**85**:304–13.
53. **Beresford SA, Weiss NS, Voigt LF, et al.** Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. *Lancet* 1997;**349**:458–61.
54. **Weiderpass E, Adami HO, Baron JA, et al.** Use of oral contraceptives and endometrial cancer risk (Sweden). *Cancer Causes Control* 1999;**10**:277–84.
55. **Beral V, Reeves G, Banks E.** Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. *BJOG* 2005;**112**:692–5.
56. **Voigt LF, Weiss NS, Chu J, et al.** Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. *Lancet* 1991;**338**:274–7.
57. **Robertson WB.** *The Endometrium*. London: Butterworths, 1981.

58. **Bergstrom A**, Pisani P, Tenet V, *et al*. Overweight as an avoidable cause of cancer in Europe. *Int J Cancer* 2001;**91**:421–30.
59. **Kaaks R**, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. *Cancer Epidemiol Biomarkers Prev* 2002;**11**:1531–43.
60. **Polednak AP**. Trends in incidence rates for obesity-associated cancers in the US. *Cancer Detect Prev* 2003;**27**:415–21.
61. **Bray F**, Loos AH, Oostindier M, *et al*. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. *Int J Cancer* 2005;**117**:123–31.
62. **Reeves GK**, Pirie K, Beral V, *et al*. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ* 2007;**335**:1134.
63. **Lepine J**, Audet-Walsh E, Gregoire J, *et al*. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. *J Clin Endocrinol Metab* 2010;**95**:2689–98.
64. **Niwa K**, Murase T, Furui T, *et al*. Enhancing effects of estrogens on endometrial carcinogenesis initiated by *N*-methyl-*N*-nitrosourea in ICR mice. *Jpn J Cancer Res* 1993;**84**:951–5.
65. **Sivridis E**, Giatromanolaki A. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. *J Clin Pathol* 2004;**57**:840–4.
66. **Archer DF**, McIntyre-Seltman K, Wilborn WW Jr, *et al*. Endometrial morphology in asymptomatic postmenopausal women. *Am J Obstet Gynecol* 1991;**165**:317–20; discussion 20–2.
67. **Korhonen MO**, Symons JP, Hyde BM, *et al*. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). *Am J Obstet Gynecol* 1997;**176**:377–80.
68. **Rance NE**. Menopause and the human hypothalamus: evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. *Peptides* 2009;**30**:111–22.
69. **Zaino RJ**. *Interpretation of Endometrial Biopsies and Curettings*. Philadelphia: Lippincott-Raven, 1996.
70. **Speroff L**, Glass R, Kase N. *Clinical Gynecological Endocrinology and Infertility*. 5th edn. Baltimore: Williams and Wilkins, 1994.
71. **Reyes FI**, Winter JS, Faiman C. Pituitary–ovarian relationships preceding the menopause. I. A cross-sectional study of serum follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. *Am J Obstet Gynecol* 1977;**129**:557–64.
72. **Overlie I**, Morkild L, Andersson AM, *et al*. Inhibin A and B as markers of menopause: a five-year prospective longitudinal study of hormonal changes during the menopausal transition. *Acta Obstet Gynecol Scand* 2005;**84**:281–5.
73. **Buckley CH**, Fox H. *Biopsy Pathology of the Endometrium*. 2nd edn. London: Arnold, 2002.
74. **Snijders MP**, de Goeij AF, Debets-Te Baerts MJ, *et al*. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. *J Reprod Fertil* 1992;**94**:363–71.
75. **Noci I**, Borri P, Scarselli G, *et al*. Morphological and functional aspects of the endometrium of asymptomatic post-menopausal women: does the endometrium really age? *Hum Reprod* 1996;**11**:2246–50.
76. **Kurman RJ**, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. *Cancer* 1985;**56**:403–12.
77. **Mutter GL**, Zaino RJ, Baak JP, *et al*. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. *Int J Gynecol Pathol* 2007;**26**:103–14.
78. **Spiegel GW**. Endometrial carcinoma in situ in postmenopausal women. *Am J Surg Pathol* 1995;**19**:417–32.
79. **Zheng W**, Liang SX, Yu H, *et al*. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. *Int J Surg Pathol* 2004;**12**:207–23.
80. **Sivridis E**, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. *Virchows Arch* 2001;**439**:118–26.
81. **Sivridis E**, Giatromanolaki A, Liberis V, *et al*. Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS). What is destined for the atypical endometrial hyperplasia? *Autophagy* 2011;**7**:74–82.
82. **Fadare O**, Zheng W. Insights into endometrial serous carcinogenesis and progression. *Int J Clin Exp Pathol* 2009;**2**:411–32.
83. **Creasman WT**, Kohler MF, Odicino F, *et al*. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. *Gynecol Oncol* 2004;**95**:593–6.
84. **Clement PB**, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. *Adv Anat Pathol* 2004;**11**:117–42.
85. **Hamilton CA**, Cheung MK, Osann K, *et al*. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. *Br J Cancer* 2006;**94**:642–6.
86. **Faratian D**, Stillie A, Busby-Earle RM, *et al*. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. *Int J Gynecol Cancer* 2006;**16**:972–8.
87. **Mendivil A**, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. *Cancer Control* 2009;**16**:46–52.
88. **Mazur MT**, Kurman RJ. *Diagnosis of Endometrial Biopsies and Curettings. A Practical Approach*. New York: Springer, 1995.
89. **Abeler VM**, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. *Cancer* 1991;**67**:3093–103.
90. **Kuwabara Y**, Susumu N, Banno K, *et al*. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan. *Jpn J Clin Oncol* 2005;**35**:23–7.
91. **Matthews RP**, Hutchinson-Colas J, Maiman M, *et al*. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. *Gynecol Oncol* 1997;**65**:206–12.
92. **Christopherson WM**, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases. *Am J Clin Pathol* 1982;**77**:534–40.
93. **Hendrickson M**, Ross J, Eifel P, *et al*. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. *Am J Surg Pathol* 1982;**6**:93–108.
94. **Kato DT**, Ferry JA, Goodman A, *et al*. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. *Gynecol Oncol* 1995;**59**:384–9.
95. **Malpica A**, Tornos C, Burke TW, *et al*. Low-stage clear-cell carcinoma of the endometrium. *Am J Surg Pathol* 1995;**19**:769–74.
96. **Slomovitz BM**, Burke TW, Eifel PJ, *et al*. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. *Gynecol Oncol* 2003;**91**:463–9.
97. **Sagr ER**, Denschlag D, Kerim-Dikeni A, *et al*. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. *Anticancer Res* 2007;**27**:1213–17.
98. **Benito V**, Lubrano A, Arencibia O, *et al*. Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. *Int J Gynecol Cancer* 2009;**19**:1364–9.
99. **Murphy KT**, Rotmensch J, Yamada SD, *et al*. Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2003;**55**:1272–6.
100. **Abeler VM**, Vergote IB, Kjørstad KE, *et al*. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. *Cancer* 1996;**78**:1740–7.
101. **Abeler VM**, Kjørstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. *Cancer* 1991;**68**:98–105.
102. **Altrabulsi B**, Malpica A, Deavers MT, *et al*. Undifferentiated carcinoma of the endometrium. *Am J Surg Pathol* 2005;**29**:1316–21.
103. **Soslow RA**, Bissonnette JP, Wilton A, *et al*. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. *Am J Surg Pathol* 2007;**31**:979–87.
104. **Sivridis E**, Giatromanolaki A. Endometrial adenocarcinoma: beliefs and scepticism. *Int J Surg Pathol* 2004;**12**:99–105.
105. **Clarke BA**, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. *J Clin Pathol* 2010;**63**:410–15.
106. **Sivridis E**, Giatromanolaki A. Endometrial adenocarcinoma: an apostasy from early views. *Gynecol Oncol* 2004;**95**:772–3.
107. **Zaino RJ**. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. *Int J Gynecol Pathol* 2009;**28**:1–9.
108. **Gemer O**, Uriev L, Voldarsky M, *et al*. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. *Eur J Surg Oncol* 2009;**35**:247–51.
109. **Alkushi A**, Abdul-Rahman ZH, Lim P, *et al*. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. *Am J Surg Pathol* 2005;**29**:295–304.
110. **Scholten AN**, Smit VT, Beerman H, *et al*. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. *Cancer* 2004;**100**:764–72.
111. **Lax SF**, Kurman RJ, Pizer ES, *et al*. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. *Am J Surg Pathol* 2000;**24**:1201–8.
112. **Taylor RR**, Zeller J, Lieberman RW, *et al*. An analysis of two versus three grades for endometrial carcinoma. *Gynecol Oncol* 1999;**74**:3–6.
113. **Melhem MF**, Tobon H. Mucinous adenocarcinoma of the endometrium: a clinicopathological review of 18 cases. *Int J Gynecol Pathol* 1987;**6**:347–55.
114. **Lax SF**, Pizer ES, Ronnett BM, *et al*. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. *Hum Pathol* 1998;**29**:924–31.
115. **Lax SF**. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. *Virchows Arch* 2004;**444**:213–23.
116. **Ross JC**, Eifel PJ, Cox RS, *et al*. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. *Am J Surg Pathol* 1983;**7**:715–29.
117. **Tashiro H**, Blazes MS, Wu R, *et al*. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. *Cancer Res* 1997;**57**:3935–40.

118. **Risinger JI**, Hayes K, Maxwell GL, *et al.* PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. *Clin Cancer Res* 1998;**4**:3005–10.
119. **Bussaglia E**, del Rio E, Matias-Guiu X, *et al.* PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. *Hum Pathol* 2000;**31**:312–17.
120. **Mutter GL**, Lin MC, Fitzgerald JT, *et al.* Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. *J Natl Cancer Inst* 2000;**92**:924–30.
121. **Caduff RF**, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. *Am J Pathol* 1995;**146**:182–8.
122. **Lax SF**, Kendall B, Tashiro H, *et al.* The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. *Cancer* 2000;**88**:814–24.
123. **Lagarda H**, Catusus L, Arguelles R, *et al.* K-ras mutations in endometrial carcinomas with microsatellite instability. *J Pathol* 2001;**193**:193–9.
124. **Tashiro H**, Lax SF, Gaudin PB, *et al.* Microsatellite instability is uncommon in uterine serous carcinoma. *Am J Pathol* 1997;**150**:75–9.
125. **Catusus L**, Machin P, Matias-Guiu X, *et al.* Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. *Hum Pathol* 1998;**29**:1160–4.
126. **Maxwell GL**, Risinger JI, Hayes KA, *et al.* Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. *Clin Cancer Res* 2000;**6**:2999–3005.
127. **Maxwell GL**, Risinger JI, Alvarez AA, *et al.* Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. *Obstet Gynecol* 2001;**97**:417–22.
128. **Rosenberg P**, Wingren S, Simonsen E, *et al.* Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator. *Gynecol Oncol* 1989;**35**:50–4.
129. **Prat J**, Oliva E, Lerma E, *et al.* Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. *Cancer* 1994;**74**:1778–83.
130. **Pradhan M**, Abeler VM, Danielsen HE, *et al.* Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. *Mod Pathol* 2006;**19**:1227–35.
131. **Sherman ME**, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. *Hum Pathol* 1995;**26**:1268–74.
132. **Tashiro H**, Isacson C, Levine R, *et al.* p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. *Am J Pathol* 1997;**150**:177–85.
133. **Kovalev S**, Marchenko ND, Gugliotta BG, *et al.* Loss of p53 function in uterine papillary serous carcinoma. *Hum Pathol* 1998;**29**:613–19.
134. **Halperin R**, Zehavi S, Habler L, *et al.* Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. *Eur J Gynaecol Oncol* 2001;**22**:122–6.
135. **Jia L**, Liu Y, Yi X, *et al.* Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. *Clin Cancer Res* 2008;**14**:2263–9.
136. **Lax SF**. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. *Pathology* 2007;**39**:46–54.
137. **Kohler MF**, Berchuck A, Davidoff AM, *et al.* Overexpression and mutation of p53 in endometrial carcinoma. *Cancer Res* 1992;**52**:1622–7.
138. **Pere H**, Tapper J, Wahlstrom T, *et al.* Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. *Cancer Res* 1998;**58**:892–5.
139. **Risinger JI**, Berchuck A, Kohler MF, *et al.* Mutations of the E-cadherin gene in human gynecologic cancers. *Nat Genet* 1994;**7**:98–102.
140. **Jeanes A**, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? *Oncogene* 2008;**27**:6920–9.
141. **Singh M**, Spoelstra NS, Jean A, *et al.* ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. *Mod Pathol* 2008;**21**:912–23.
142. **Holcomb K**, Delatorre R, Pedemonte B, *et al.* E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. *Obstet Gynecol* 2002;**100**:1290–5.
143. **Mell LK**, Meyer JJ, Tretiakova M, *et al.* Prognostic significance of E-cadherin protein expression in pathological stage I–III endometrial cancer. *Clin Cancer Res* 2004;**10**:5546–53.
144. **Stefansson IM**, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. *J Clin Oncol* 2004;**22**:1242–52.
145. **Announcements**. FIGO stages - 1988 revision. *Gynecol Oncol* 1989;**35**:125–7.
146. **Zaino RJ**, Kurman RJ, Diana KL, *et al.* The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. *Cancer* 1995;**75**:81–6.
147. **Moreno-Bueno G**, Hardisson D, Sanchez C, *et al.* Abnormalities of the APC/beta-catenin pathway in endometrial cancer. *Oncogene* 2002;**21**:7981–90.
148. **Fukuchi T**, Sakamoto M, Tsuda H, *et al.* Beta-catenin mutation in carcinoma of the uterine endometrium. *Cancer Res* 1998;**58**:3526–8.
149. **Machin P**, Catusus L, Pons C, *et al.* CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. *Hum Pathol* 2002;**33**:206–12.